Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Age-related macular degeneration (AMD ... we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced form of dry AMD. Pegcetacoplan (Syfovre) is the first ...

The large economic burden from late-stage age-related macular degeneration on patients, caregivers, and healthcare systems is from direct and indirect medical expenses, including well-being and ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Astellas has suffered another major setback with geographic atrophy (GA ... in the US since 2023 for GA secondary to age-related macular degeneration (AMD), a leading cause of blindness, given ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

The company will also evaluate secondary to age-related macular degeneration in Japan. Geographic atrophy is a progressive form of AMD that can cause irreversible vision loss, with no treatments ...

Pulsesight Therapeutics SAS has submitted a clinical trial authorization (CTA) to the French authority ANSM seeking to conduct a first-in-human phase I trial of PST-611 for dry age-related macular ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ...

Avacincaptad pegol (ACP) is an investigational drug for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) that has been submitted for Conditional Approval in ...